world
Reader Responses to GLP-1 Weight Loss Drugs and Insurance Coverage Changes
Readers of The Boston Globe have shared varied opinions on GLP-1 medications for obesity treatment following a February 22 article. Some highlight the drugs' benefits for health conditions beyond weight loss, while others question obesity as a disease and oppose insurance subsidies.
The Boston GlobeAudio version
Tap play to generate a narrated version.
Readers responded to a February 22 Boston Globe article titled 'The GLP-1 Trap,' which discussed challenges with GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound. These drugs, part of the glucagon-like peptide-1 receptor agonist class, are used for weight management and type 2 diabetes.
The responses reflect debates on obesity classification, insurance coverage, and drug affordability.
Several readers affirmed obesity as a recognized disease. Organizations including the Centers for Disease Control and Prevention, American Medical Association, National Institutes of Health, American Academy of Pediatrics, and World Health Organization classify obesity as a chronic disease.
One reader noted that denying coverage for these medications affects individuals who maintain diets and exercise but struggle with weight loss.
A reader with non-alcoholic fatty liver disease, pre-type 2 diabetes, and high blood pressure reported using Mounjaro, which normalized their liver enzymes, A1C levels, and reduced blood pressure.
Another self-pays $449 per month for Zepbound vials and described the ability to afford it as a privilege. These accounts illustrate the drugs' applications for multiple conditions. Obesity rates have increased in the United States and parallel rises have been observed in some laboratory animals on controlled diets with unchanged calorie and nutrient intake.
Researchers are investigating potential environmental factors, changes in food supply, or epigenetic influences across species. This suggests complexity in obesity causes beyond individual choices.
Some readers contested obesity as a disease, comparing it to smoking or gun deaths as outcomes of personal decisions.
They argued against insurance subsidizing the costs, stating individuals should bear the expenses of their choices. The drugs remain expensive, with insurers facing challenges in covering widespread use. Other responses criticized high pharmaceutical prices charged to those in need.
